Results 1 to 10 of about 77,701 (209)

Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin [PDF]

Microbial Cell, 2014
The human pathology Wilson disease (WD) is characterized by toxic copper (Cu) accumulation in brain and liver, resulting in, among other indications, mitochondrial dysfunction and apoptosis of hepatocytes.
Pieter Spincemaille, Gursimran Chandhok, Andree Zibert, Hartmut Schmidt, Jef Verbeek, Patrick Chaltin, Bruno P.A. Cammue, David Cassiman, Karin Thevissen   +8 more
doaj   +6 more sources

Comparative Efficacy of Angiotensin II Type 1 Receptor Blockers Against Ventilator‐Induced Diaphragm Dysfunction in Rats [PDF]

Clinical and Translational Science, 2021
Mechanical ventilation (MV) is a life‐saving intervention for many critically ill patients. Unfortunately, prolonged MV results in the rapid development of inspiratory muscle weakness due to diaphragmatic atrophy and contractile dysfunction (termed ...
Stephanie E. Hall, Bumsoo Ahn, Ashley J. Smuder, Aaron B. Morton, J. Matthew Hinkley, Michael P. Wiggs, Kurt J. Sollanek, Hayden Hyatt, Scott K. Powers   +8 more
doaj   +2 more sources

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy. [PDF]

J Renin Angiotensin Aldosterone Syst, 2020
Introduction: The aims of this study were to assess the renal expression of angiotensin II type 1 receptor (AT1R), angiotensin II type 2 receptor (AT2R), and MAS receptor in human type 2 diabetic nephropathy (DN). Materials and methods: In total, 115 patients diagnosed with DN by renal biopsy were enrolled in this study.
Ma YP, Yang Y, Jiang SM, Liu L, Zhang Z, Wang YN, Zou GM, Li WG.   +7 more
europepmc   +4 more sources

Unique mode of binding between angiotensin II type 1 receptor and its blockers

Clinical and Experimental Hypertension, 2019
BACKGROUND: We hypothesized that the 5-oxo-1,2,4-oxadiazole moiety of azilsartan (AZL), which represents a small difference in the molecular structures of AZL and candesartan (CAN) [angiotensin II type 1 receptor (AT1R) blockers], may be responsible for ...
Yoshino Matsuo, Yasunori Suematsu, Sayo Tomita, Kohei Tashiro, Takashi Kuwano, Ken Kitajima, Shin-ichiro Miura   +6 more
doaj   +3 more sources

Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications. [PDF]

Neurotox Res, 2017
Angiotensin II receptor blockers (ARBs) are one of the most frequently recommended antihypertensive drugs. Apart from their activity towards the circulatory system, ARBs also penetrate the blood-brain barrier and display neuroprotective effects. Kynurenic acid (KYNA) is an endogenous metabolite of tryptophan produced by kynurenine aminotransferase II ...
Zakrocka I, Targowska-Duda KM, Wnorowski A, Kocki T, Jóźwiak K, Turski WA.   +5 more
europepmc   +4 more sources

Beyond blood pressure: the renin-angiotensin system as an innovative driver and therapeutic target in pathological scarring [PDF]

Frontiers in Pharmacology
Pathological scarring, a fibroproliferative disorder, imposes a substantial burden on affected individuals. This review explores the pivotal role of the local cutaneous renin-angiotensin system (RAS) in the pathogenesis of pathological scarring.
Bang-Hui Shi, Xin-Ge Zhang, Qing-Qing Fang, Kai Xu, Xiao-Ling Chen, Wei-Qiang Tan, Shou-Jie Wang, Shou-Jie Wang   +7 more
doaj   +2 more sources

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies, observational in design, appear to use biased methods that can distort the interaction between RAAS inhibitor use and COVID‐19 risk. This study assessed the extent of bias
Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström   +3 more
doaj   +1 more source

Losartan improved hippocampal long‐term potentiation impairment induced by repeated LPS injection in rats

Physiological Reports, 2021
Cognitive impairment has been known as a common consequence of brain inflammation. Long‐term potentiation (LTP), the generally accepted cellular mechanism for memory formation in the mammalian brain, has been shown to be suppressed by inflammation ...
Mahmoud Hosseini, Hossein Salmani, Yousef Baghcheghi   +2 more
doaj   +1 more source

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19

Biomolecules, 2021
Angiotensin II (Ang II) may contain a charge relay system (CRS) involving Tyr/His/carboxylate, which creates a tyrosinate anion for receptor activation. Energy calculations were carried out to determine the preferred geometry for the CRS in the presence ...
Graham J. Moore, Jose M. Pires, Konstantinos Kelaidonis, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, John M. Matsoukas   +6 more
doaj   +1 more source

Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort [PDF]

Journal of Preventive Medicine and Public Health, 2020
Objectives: The objective of this study was to estimate the risk of lung cancer in relation to angiotensin II receptor blocker (ARB) use among patients with hypertension from the Korean National Health Insurance Service-National Health Screening Cohort ...
Sungji Moon, Hae-Young Lee, Jieun Jang, Sue K. Park   +3 more
doaj   +1 more source